

# CITATION REPORT

List of articles citing

## Compliance of sildenafil treatment for erectile dysfunction and factors affecting it

DOI: 10.1038/sj.ijir.3901379

International Journal of Impotence Research, 2006, 18, 146-9.

**Source:** <https://exaly.com/paper-pdf/40447953/citation-report.pdf>

**Version:** 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
74	Bibliography. Current world literature. Reconstructive surgery. <i>Current Opinion in Urology</i> , <b>2006</b> , 16, 460-38		
73	Management of sildenafil treatment failures. <i>Current Opinion in Urology</i> , <b>2006</b> , 16, 449-59	2.8	33
72	Positive effect of counseling and dose adjustment in patients with erectile dysfunction who failed treatment with sildenafil. <i>European Urology</i> , <b>2006</b> , 50, 134-40	10.2	54
71	Phosphodiesterase type 5 inhibitor therapy: identifying and exploring what attributes matter more to clinicians and patients in the management of erectile dysfunction. <i>Current Medical Research and Opinion</i> , <b>2007</b> , 23, 3189-98	2.5	10
70	Involvement of alpha-receptors and potassium channels in the mechanism of action of sildenafil citrate. <i>International Journal of Impotence Research</i> , <b>2007</b> , 19, 551-7	2.3	12
69	Preference for gender of health care provider in management of erectile dysfunction. <i>International Journal of Impotence Research</i> , <b>2007</b> , 19, 474-9	2.3	7
68	Optimizing response to phosphodiesterase type 5 inhibitors. <i>Current Sexual Health Reports</i> , <b>2007</b> , 4, 1-6	1.2	1
67	Chronic dosing of phosphodiesterase type 5 inhibitors. <i>Current Sexual Health Reports</i> , <b>2008</b> , 5, 65-69	1.2	
66	JSSM Guidelines for erectile dysfunction. <i>International Journal of Urology</i> , <b>2008</b> , 15, 564-76	2.3	8
65	Acceptance of and discontinuation rate from erectile dysfunction oral treatment in patients following bilateral nerve-sparing radical prostatectomy. <i>European Urology</i> , <b>2008</b> , 53, 564-70	10.2	70
64	Giving patients with erectile dysfunction the opportunity to try all three available phosphodiesterase type 5 inhibitors contributes to better long-term treatment compliance. <i>Journal of Sexual Medicine</i> , <b>2008</b> , 5, 469-75	1.1	33
63	Erectile dysfunction, testosterone deficiency, metabolic syndrome and prostatic disease in Taiwan. <i>Journal of Men's Health</i> , <b>2008</b> , 5, 289-296	1.2	2
62	2009 update on phosphodiesterase type 5 inhibitor therapy part 2: updates on optimal utilization for sexual concerns and rare toxicities in this class. <i>Journal of Sexual Medicine</i> , <b>2009</b> , 6, 2352-64; quiz 2365-6	1.1	31
61	Phosphodiesterase type 5 inhibitors for the management of erectile dysfunction: preference and adherence to treatment. <i>Current Pharmaceutical Design</i> , <b>2009</b> , 15, 3486-95	3.3	16
60	The female factor: predicting compliance with a post-prostatectomy erectile preservation program. <i>Journal of Sexual Medicine</i> , <b>2010</b> , 7, 3659-65	1.1	20
59	Satisfaction profiles in men using intracavernosal injection therapy. <i>Journal of Sexual Medicine</i> , <b>2011</b> , 8, 512-7	1.1	18
58	Favorable female sexual function is associated with patient satisfaction after inflatable penile prosthesis implantation. <i>Journal of Sexual Medicine</i> , <b>2011</b> , 8, 1996-2001	1.1	20

57	PDE5 inhibitor treatment options for urologic and non-urologic indications: 2012 update. <i>Current Pharmaceutical Design</i> , <b>2012</b> , 18, 5590-606	3.3	14
56	Primary Care Evaluation and Treatment of Erectile Dysfunction. <b>2012</b> , 105-119		1
55	Couples' reasons for adherence to, or discontinuation of, PDE type 5 inhibitors for men with erectile dysfunction at 12 to 24-month follow-up after a 6-month free trial. <i>Journal of Sexual Medicine</i> , <b>2012</b> , 9, 857-65	1.1	23
54	Dropout in the treatment of erectile dysfunction with PDE5: a study on predictors and a qualitative analysis of reasons for discontinuation. <i>Journal of Sexual Medicine</i> , <b>2012</b> , 9, 2361-9	1.1	77
53	The Intra- and Inter-Personal Dynamics Associated with Consuming Sensitive Products: Understanding the Consumption of Erectile Function Aids Using Dimensional Qualitative Research. <i>Psychology and Marketing</i> , <b>2012</b> , 29, 1-14	3.9	
52	PDE5 inhibitors: considerations for preference and long-term adherence. <i>International Journal of Clinical Practice</i> , <b>2013</b> , 67, 768-80	2.9	73
51	A 6-month, prospective, observational study of PDE5 inhibitor treatment persistence and adherence in Middle Eastern and North African men with erectile dysfunction. <i>Current Medical Research and Opinion</i> , <b>2013</b> , 29, 707-17	2.5	10
50	A 6 month, prospective, observational study of PDE5 inhibitor treatment persistence and adherence in Latin American men with erectile dysfunction. <i>Current Medical Research and Opinion</i> , <b>2013</b> , 29, 695-706	2.5	10
49	SOP conservative (medical and mechanical) treatment of erectile dysfunction. <i>Journal of Sexual Medicine</i> , <b>2013</b> , 10, 130-71	1.1	117
48	Assessing satisfaction in men and their female partners after treatment with phosphodiesterase type 5 inhibitors for erectile dysfunction. <i>International Journal of Impotence Research</i> , <b>2013</b> , 25, 178-82	2.3	8
47	An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors. <i>Expert Opinion on Pharmacotherapy</i> , <b>2013</b> , 14, 1333-44	4	72
46	Endothelium-independent relaxant effect of <i>Rubus coreanus</i> extracts in corpus cavernosum smooth muscle. <i>Journal of Sexual Medicine</i> , <b>2013</b> , 10, 1720-9	1.1	5
45	High patient satisfaction after inflatable penile prostheses implantation correlates with female partner satisfaction. <i>Journal of Sexual Medicine</i> , <b>2013</b> , 10, 2774-81	1.1	20
44	Exploring the association between erectile rigidity and treatment adherence with sildenafil. <i>Journal of Sexual Medicine</i> , <b>2013</b> , 10, 1861-6	1.1	5
43	Improvement in erection hardness and intercourse success with first dose of sildenafil citrate 100 mg. <i>International Journal of General Medicine</i> , <b>2013</b> , 6, 849-54	2.3	5
42	PDE5 inhibitor treatment persistence and adherence in Brazilian men: post-hoc analyses from a 6-month, prospective, observational study. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , <b>2014</b> , 40, 390-9	2	12
41	Reasons and predictive factors for discontinuation of PDE-5 inhibitors despite successful intercourse in erectile dysfunction patients. <i>International Journal of Impotence Research</i> , <b>2014</b> , 26, 87-93 <sup>2.3</sup>		22
40	Data on the utilization of treatment modalities for ED in Taiwan in the era of PDE5 inhibitors. <i>International Journal of Impotence Research</i> , <b>2014</b> , 26, 141-5	2.3	10

39	Adherence to phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction in long-term users: how do men use the inhibitors?. <i>Sexual Medicine</i> , <b>2014</b> , 2, 96-102	2.7	11
38	Integrative Approaches to the Treatment of Erectile Dysfunction. <i>Current Sexual Health Reports</i> , <b>2014</b> , 6, 114-123	1.2	8
37	Assessing satisfaction in men with premature ejaculation after dapoxetine treatment in real-world practice. <i>International Journal of Clinical Practice</i> , <b>2015</b> , 69, 1326-33	2.9	15
36	Failure to attain stretched penile length after intracavernosal injection of a vasodilator agent is predictive of veno-occlusive dysfunction on penile duplex Doppler ultrasonography. <i>Andrology</i> , <b>2015</b> , 3, 919-23	4.2	10
35	Expectations do not Influence the Response to Phosphodiesterase Type 5 Inhibitor Therapy for Erectile Dysfunction. <i>Pharmacy (Basel, Switzerland)</i> , <b>2015</b> , 3, 295-306	2	
34	Intracavernosal Injection for the Diagnosis, Evaluation, and Treatment of Erectile Dysfunction: A Review. <i>Sexual Medicine Reviews</i> , <b>2015</b> , 3, 11-23	5.6	30
33	A comparison of different oral therapies versus no treatment for erectile dysfunction in 196 radical nerve-sparing radical prostatectomy patients. <i>International Journal of Impotence Research</i> , <b>2015</b> , 27, 1-5	2.3	10
32	Validation of Portuguese version of Quality of Erection Questionnaire (QEQ) and comparison to International Index of Erectile Function (IIEF) and RAND 36-Item Health Survey. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , <b>2015</b> , 41, 155-67	2	5
31	Guía de disfunción eréctil. Sociedad Colombiana de Urología. <i>Urologia Colombiana</i> , <b>2015</b> , 24, 185.e1-185.e220.1		2
30	Results from an online survey investigating ED patients' insights and treatment expectations. <i>International Journal of Impotence Research</i> , <b>2015</b> , 27, 191-6	2.3	12
29	Erectile Dysfunction Medication Use in Veterans Eligible for Medicare Part D. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , <b>2016</b> , 22, 818-24	1.9	6
28	Sexual Dysfunction in Type 2 Diabetes at Diagnosis: Progression over Time and Drug and Non-Drug Correlated Factors. <i>PLoS ONE</i> , <b>2016</b> , 11, e0157915	3.7	18
27	Current role of local treatments for erectile dysfunction in the real-life setting. <i>Current Opinion in Urology</i> , <b>2016</b> , 26, 123-8	2.8	1
26	Management of Sexual Dysfunction in Men and Women. <b>2016</b> ,		6
25	Drug therapy for erectile dysfunction. <b>2016</b> , 172-193		
24	Psychological assessment of patients with ED. <b>2016</b> , 120-128		
23	Nouvelle alternative locale dans le traitement de la dysfonction Érectile : l'offre thérapeutique s'Étoffe. <i>Sexologies</i> , <b>2016</b> , 25, 153-159	0.5	
22	First-generation phosphodiesterase type 5 inhibitors dropout: a comprehensive review and meta-analysis. <i>Andrology</i> , <b>2016</b> , 4, 1002-1009	4.2	42

21	Erectile dysfunction. <i>Nature Reviews Disease Primers</i> , <b>2016</b> , 2, 16003	51.1	246
20	Alprostadil cream in the treatment of erectile dysfunction: clinical evidence and experience. <i>Therapeutic Advances in Urology</i> , <b>2016</b> , 8, 249-256	3.2	8
19	Minimally invasive infrapubic inflatable penile prosthesis implant for erectile dysfunction: evaluation of efficacy, satisfaction profile and complications. <i>International Journal of Impotence Research</i> , <b>2016</b> , 28, 4-8	2.3	39
18	How Did Erectile Dysfunction Become "Natural"? A Review of the Critical Social Scientific Literature on Medical Treatment for Male Sexual Dysfunction. <i>Journal of Sex Research</i> , <b>2017</b> , 54, 486-506	4	9
17	What Women Want-An Explorative Study on Women's Attitudes Toward Sexuality Boosting Medication in a Sample of Swiss Women. <i>Journal of Sexual Medicine</i> , <b>2017</b> , 14, 404-412	1.1	2
16	Low-energy Shock Wave Therapy-A Novel Treatment Option for Erectile Dysfunction in Men With Cardiovascular Disease. <i>Urology</i> , <b>2017</b> , 109, 19-26	1.6	7
15	Integrating Sexual Partners into Pharmacological Sex Therapy. <b>2017</b> , 453-467		1
14	[Avanafil for the treatment of erectile dysfunction in practice. Non-interventional study AVANTI]. <i>MMW Fortschritte Der Medizin</i> , <b>2017</b> , 159, 16-21	0	1
13	Non-invasive Management Options for Erectile Dysfunction When a Phosphodiesterase Type 5 Inhibitor Fails. <i>Drugs and Aging</i> , <b>2018</b> , 35, 175-187	4.7	12
12	Resumen de la Guía de Práctica Clínica de Disfunción Eréctil [Sociedad Colombiana de Urología]. <i>Urología Colombiana</i> , <b>2018</b> , 27, 203-213	0.1	
11	[Do phosphodiesterase type 5 inhibitors generics enhance discontinuation due to price with patients suffering from erectile dysfunction?]. <i>Progres En Urologie</i> , <b>2019</b> , 29, 326-331	0.9	1
10	Different Evaluations Exist between Men with Erectile Dysfunction and Their Female Partners When Using Erectile Hardness Model: An Interesting, Observational, and Cross-Sectional Field Survey. <i>BioMed Research International</i> , <b>2020</b> , 2020, 2302348	3	2
9	Men's beliefs about treatment for erectile dysfunction-what influences treatment use? A systematic review. <i>International Journal of Impotence Research</i> , <b>2021</b> , 33, 16-42	2.3	1
8	Can low intensity shockwave therapy match the efficacy of phosphodiesterase-5 inhibitors for erectile dysfunction treatment? A pooled data analysis from two randomized clinical trials. <i>International Journal of Impotence Research</i> , <b>2021</b> , 33, 383-385	2.3	
7	Considerations for prescribing pharmacotherapy for the treatment of erectile dysfunction. <i>Expert Opinion on Pharmacotherapy</i> , <b>2021</b> , 22, 821-834	4	3
6	Phenomenological and existential contributions to the study of erectile dysfunction. <i>Medicine, Health Care and Philosophy</i> , <b>2021</b> , 24, 597-608	2	1
5	Evaluation of Therapy Effectiveness in Men with Different Erectile Dysfunction Severity. <i>Health of Man</i> , <b>2021</b> , 71-78	0.1	
4	Practical Guidelines for the Treatment of Erectile Dysfunction and Peyronie's Disease. <b>2020</b> , 357-392		1

- 3 Intracavernous Stem Cell Transplantation in Erectile Dysfunction: Modification of Adhesive Properties of Stem Cells Increases Their Ability to Restore Contractile and Phosphatase Activity of Cavernous Tissue Damaged by Hyperglycemia. *Health of Man*, **2018**, 72-75 0.1
- 2 Preference for and adherence to oral phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction. *Patient Preference and Adherence*, **2008**, 2, 149-55 2.4 7
- 1 Medication strategies regarding erectile dysfunction and associated treatment drop out and compliance <sup>1</sup>A retrospective study of 516 patients. **2022**, 0